Advertisement

Current Allergy and Asthma Reports

, Volume 7, Issue 4, pp 274–279 | Cite as

Plasmapheresis for chronic inflammatory demyelinating polyradiculoneuropathy

  • Man Mohan MehndirattaEmail author
  • Avinash Chandra Singh
Article

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated disorder characterized by progressive or relapsing symmetrical motor or sensory symptoms and signs in more than one limb, developing over at least 2 months. It may cause prolonged periods of disability and even death. Evidence from trials suggests that plasma exchange provides significant short-term benefit in about two thirds of patients with chronic inflammatory demyelinating polyradiculoneuropathy. This review evaluates the role of plasmapheresis in CIDP.

Keywords

Plasma Exchange Compound Muscle Action Potential Demyelinating Polyneuropathy Experimental Autoimmune Neuritis Compound Muscle Action Potential Amplitude 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Köller H, Kieseier BC, Jander S, Hartung HP: Medical progress Chronic inflammatory demyelinating polyneuropathy N Engl J Med 2005, 352: 1343–1356.PubMedCrossRefGoogle Scholar
  2. 2.
    Austin JH: Recurrent polyneuropathies and their corticosteroid treatment; with five year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain 1958, 81: 157–192.PubMedCrossRefGoogle Scholar
  3. 3.
    Thomas PK, Lascelles RG, Hallpike JF, Hewer RL: Recurrent and chronic relapsing Guillain-Barre polyneuritis. Brain 1969, 92: 589–606.PubMedCrossRefGoogle Scholar
  4. 4.
    Dyck PJ, Lais AC, Ohta M, et al.: Chronic inflammatory polyradiculo-neuropathy. Mayo Clinic Proc 1975, 50: 621–637.Google Scholar
  5. 5.
    Prineas JW, McLeod JG: Chronic relapsing polyneuritis. J Neurol Sci 1976, 27: 427–458.PubMedCrossRefGoogle Scholar
  6. 6.
    Bouchard C, Lacrocoix C, Plante V, et al.: Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 1999, 52: 498–503.PubMedGoogle Scholar
  7. 7.
    Bosch PE, Smith BE: Disease of peripheral nerves. In Neurology in Clinical Practice. Edited by Bradley WG, Daroff RB, Fenichel GM, Marsden ED. London: Butterworth-Heinemann; 2004: 2299–2401.Google Scholar
  8. 8.
    Hughes R: Chronic in flammatory demyelinating polyradiculineuropathy. Pract Neurol 2002, 2: 198–207.CrossRefGoogle Scholar
  9. 9.
    Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP): report from an ad hoc subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991, 41: 617–618.Google Scholar
  10. 10.
    Saperstein DS, Katz JS, Amato AA, Barohn RJ: Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001, 24: 311–324.PubMedCrossRefGoogle Scholar
  11. 11.
    Hughes R, Bensa S, Willison H, et al. for the Inflammatory NeuropathyCauseandTreatment (INCAT) Group: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001, 50: 195–201.PubMedCrossRefGoogle Scholar
  12. 12.
    Latov N: Diagnosis of CIDP. Neurology 2002, 59(Suppl 6):S2–S6.PubMedGoogle Scholar
  13. 13.
    Hahn AF: Experimental allergic neuritis (EAN) as a model for the immune-mediated demyelinating neuropathies. Revue Neurologique (Paris) 1996, 152: 328–332Google Scholar
  14. 14.
    Van Doorn PA, Brand A, Vermeulen M: Clinical significance of antibodies against peripheral nerve tissue in inflammatory polyneuropathy. Neurology 1987, 37: 1798–1802.PubMedGoogle Scholar
  15. 15.
    Yan WX, Archelos JJ, Hartung HP, et al.: P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001, 50: 286–292.PubMedCrossRefGoogle Scholar
  16. 16.
    Dyck PJ, Daube J, O’Brien P, et al.: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986, 314: 461–465.PubMedCrossRefGoogle Scholar
  17. 17.
    Dyck PJ, Pineda A, Swanson C, et al.: The Mayo Clinic experience with plasma exchange in chronic inflammatory-demyelinating polyneuropathy (CIDP). Prog Clin Biol Res 1982, 106: 197–204.PubMedGoogle Scholar
  18. 18.
    Hahn AF, Bolton CF, Pillay N, et al.: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. A double blind, sham-controlled, crossover study. Brain 1996, 119(Pt 4):1055–1066.PubMedCrossRefGoogle Scholar
  19. 19.
    Mehndiratta MM, Hughes RAC, Agarwal P: Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004, 3: CD003906.pub2. DOI: 10.1002/14651858.Google Scholar
  20. 20.
    Hahn AF, Bolton CF, Zochodne D, Feasby TE: Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo controlled, cross-over study. Brain 1996, 119: 1067–1077.PubMedCrossRefGoogle Scholar
  21. 21.
    Mendell JR, Barohn RJ, Freimer ML, et al.: Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001, 56: 445–449.PubMedGoogle Scholar
  22. 22.
    Dalakas MC: Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002, 59(Suppl 6):S13–S21.PubMedGoogle Scholar
  23. 23.
    Van Schaik IN, Winer JB, De Haan R, Vermeulen M: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002, 2: CD001797.Google Scholar
  24. 24.
    Sghirlanzoni A, Solari A, Ciano C, et al.: Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients. Neurol Sci 2000, 21: 31–37.PubMedCrossRefGoogle Scholar
  25. 25.
    Mehndiratta MM, Hughes RA: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002, 1: CD002062.Google Scholar
  26. 26.
    Ropper AH: Current treatments for CIDP. Neurology 2003, 60(Suppl 3):S16–S22.PubMedGoogle Scholar
  27. 27.
    Vermeulen M, van Doorn PA, Brand A, et al.: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993, 56: 36–39.PubMedCrossRefGoogle Scholar
  28. 28.
    Khatri BO, McQuillen MP, Harrington GJ, et al.: Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985, 35: 312–319.PubMedGoogle Scholar
  29. 29.
    Tsokos GC, Balow JE: Immunosuppressive agents and plasmapheresis in immunological disorders. J Immunopharmacol 1985, 7: 1–15.PubMedCrossRefGoogle Scholar
  30. 30.
    Heininger K, Liebert UG, Toyka KV, et al.: Chronic inflammatory polyneuropathy. Reduction of nerve conduction velocities in monkeys by systemic passive transfer of immunoglobulin G. J Neurol Sci 1984, 66: 1–14.PubMedCrossRefGoogle Scholar
  31. 31.
    Pollard JD, McLeod JG, Gatenby P, et al.: Prediction of response to plasma exchange in chronic relapsing polyneuropathy. A clinico-pathological correlation. J Neurol Sci 1983, 58: 269–287.PubMedCrossRefGoogle Scholar
  32. 32.
    De Luca G, Lugaresi A, Iarlori C, et al.: Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1999, 95: 190–194.PubMedCrossRefGoogle Scholar
  33. 33.
    Levy RL, Newkirk R, Ochoa J: Treating chronic relapsing Guillain-Barré syndrome by plasma exchange. Lancet 1979, 2: 259–260.PubMedCrossRefGoogle Scholar
  34. 34.
    Server AC, Lefkowith J, Braine H, et al.: Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange. Ann Neurol 1979, 6: 258–261.PubMedCrossRefGoogle Scholar
  35. 35.
    Bromberg MB, Feldman EL, Jaradeh S, Albers JW: Prognosis in long-term immunosuppressive treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy. J Clin Epidemiol 1992, 45: 47–52.PubMedCrossRefGoogle Scholar
  36. 36.
    Dyck PJ, O’Brien PC, Oviatt KF, et al.: Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982, 11: 136–141.PubMedCrossRefGoogle Scholar
  37. 37.
    Pollard JD: A critical review of therapies in acute and chronic inflammatory demyelinating polyneuropathies. Muscle Nerve 1987, 10: 214–221.PubMedCrossRefGoogle Scholar
  38. 38.
    Gorson KC, Allam G, Ropper AH: Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997, 48: 321–328.PubMedGoogle Scholar
  39. 39.
    Dyck PJ, Litchy WJ, Kratz KM, et al.: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994, 36: 838–845.PubMedCrossRefGoogle Scholar
  40. 40.
    Hughes RAC, Swan AV, van Doorn PA: Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy (Cochrane Review). Cochrane Database Syst Rev 2004, 4: 10.1002/14651858. CD003280.pub2.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.#502, Academic Block, Department of NeurologyG.B. Pant HospitalNew DelhiIndia

Personalised recommendations